Regenxbio (RGNX) Depreciation & Amortization (CF) (2015 - 2025)

Regenxbio's Depreciation & Amortization (CF) history runs 11 years deep, the most recent figure standing at $3.9 million for Q4 2025.

• In Q4 2025, Depreciation & Amortization (CF) fell 3.47% year-over-year to $3.9 million; the TTM figure through Dec 2025 stood at $15.6 million (down 3.61% YoY), while the FY2025 annual figure was $15.6 million, down 3.61% from the prior year.
• Depreciation & Amortization (CF) for Q4 2025 stood at $3.9 million, roughly flat from $3.9 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $4.4 million in Q2 2023, with the low at $1.9 million in Q1 2021.
• The 5-year median for Depreciation & Amortization (CF) is $3.9 million (2025), against an average of $3.6 million.
• The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) surged 67.8% in 2023, then slipped 9.4% in 2024.
• Regenxbio's Depreciation & Amortization (CF) stood at $2.6 million in 2021, then surged by 58.33% to $4.1 million in 2022, then gained by 4.58% to $4.3 million in 2023, then retreated by 7.11% to $4.0 million in 2024, then decreased by 3.47% to $3.9 million in 2025.
• Business Quant data shows RGNX's Depreciation & Amortization (CF) at $3.9 million in Q4 2025, $3.9 million in Q3 2025, and $3.9 million in Q2 2025.